A molecular signature of the Nottingham prognostic index in breast cancer

The Nottingham prognostic index (NPI) is a widely used clinicopathological staging system for breast cancer prognostication. Using a step-wise classification approach where breast tumor expression profiles were first divided into general "molecular subtypes" [estrogen receptor (ER)+, ER-,...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2004-05, Vol.64 (9), p.2962-2968
Main Authors: YU, Kun, CHEE HOW LEE, PUAY HOON TAN, GA SZE HONG, SIEW BOK WEE, CHOW YIN WONG, TAN, Patrick
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Breast Neoplasms - classification
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Cluster Analysis
Gene Expression Profiling
Humans
Medical sciences
Neoplasm Staging
Pharmacology. Drug treatments
Prognosis
Receptor, ErbB-2 - biosynthesis
Receptor, ErbB-2 - genetics
Receptors, Estrogen - biosynthesis
Receptors, Estrogen - genetics
Survival Rate
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Nottingham prognostic index (NPI) is a widely used clinicopathological staging system for breast cancer prognostication. Using a step-wise classification approach where breast tumor expression profiles were first divided into general "molecular subtypes" [estrogen receptor (ER)+, ER-, ERBB2+], followed by an independent analysis of each subtype, we identified a 62-gene expression signature (NPI-ES) highly correlated to the NPI in ER+ tumors. The NPI-ES classified the majority of ER+ tumors into two distinct groups with high confidence and was significantly correlated to NPI status in two independent sets of ER+ tumors derived from different centers. The NPI-ES is comparable to the classical NPI in identifying patients likely to exhibit a poor clinical prognosis, as well as to a recently described "prognosis signature" for breast cancer. Our findings demonstrate how expression profiling can complement classical staging systems employing histopathological parameters scored over a continuous range of values.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-03-2430